Lynn Seely Buys 175,000 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CEO Lynn Seely acquired 175,000 shares of Lyell Immunopharma stock in a transaction dated Friday, March 14th. The shares were acquired at an average price of $0.61 per share, with a total value of $106,750.00. Following the completion of the acquisition, the chief executive officer now directly owns 712,500 shares of the company’s stock, valued at approximately $434,625. The trade was a 32.56 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Lyell Immunopharma Trading Down 8.3 %

Shares of Lyell Immunopharma stock opened at $0.53 on Friday. The company has a market capitalization of $157.45 million, a P/E ratio of -0.68 and a beta of -0.41. The stock has a fifty day simple moving average of $0.61 and a 200 day simple moving average of $0.89. Lyell Immunopharma, Inc. has a 12-month low of $0.48 and a 12-month high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The firm had revenue of $0.01 million during the quarter. On average, analysts predict that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating and set a $1.00 price target on shares of Lyell Immunopharma in a research note on Thursday, March 13th.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors have recently added to or reduced their stakes in LYEL. Public Employees Retirement System of Ohio bought a new position in shares of Lyell Immunopharma in the fourth quarter valued at approximately $64,000. venBio Partners LLC bought a new position in Lyell Immunopharma in the 4th quarter valued at $4,545,000. Two Sigma Advisers LP grew its stake in Lyell Immunopharma by 143.8% in the 4th quarter. Two Sigma Advisers LP now owns 306,400 shares of the company’s stock valued at $196,000 after purchasing an additional 180,700 shares during the period. Millennium Management LLC increased its position in shares of Lyell Immunopharma by 34.8% during the 4th quarter. Millennium Management LLC now owns 957,507 shares of the company’s stock valued at $613,000 after purchasing an additional 247,440 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Lyell Immunopharma by 13.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 308,551 shares of the company’s stock worth $197,000 after purchasing an additional 36,555 shares during the period. 66.05% of the stock is owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.